Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
10th May 20233:30 pmRNSDirector/PDMR Shareholding
10th May 202312:00 pmRNSBlock listing Interim Review
10th May 20238:51 amRNSHolding(s) in Company
4th May 20232:48 pmRNSResult of AGM
27th Apr 202312:00 pmRNS1st Quarter Results
25th Apr 20232:30 pmRNSIndivior to Participate in Conference
25th Apr 20239:26 amRNSHolding(s) in Company
20th Apr 20238:43 amRNSHolding(s) in Company
18th Apr 20238:09 amRNSHolding(s) in Company
17th Apr 20234:25 pmRNSHolding(s) in Company
11th Apr 20232:00 pmRNSNotice of Q1 Results
6th Apr 202312:24 pmRNSHolding(s) in Company
3rd Apr 20239:35 amRNSTotal Voting Rights
30th Mar 20232:37 pmRNSHolding(s) in Company
28th Mar 20233:21 pmRNSHolding(s) in Company
27th Mar 202311:42 amRNSAnnual Financial Report
24th Mar 20232:30 pmRNSDirector/PDMR Shareholding
23rd Mar 202310:02 amRNSBlock Listing of Shares
22nd Mar 20233:00 pmRNSDirector/PDMR Shareholding
16th Mar 20232:30 pmRNSDirector/PDMR Shareholding
15th Mar 20232:30 pmRNSDirector/PDMR Shareholding
13th Mar 20234:04 pmRNSDirector/PDMR Shareholding
13th Mar 20232:36 pmRNSHolding(s) in Company
8th Mar 20239:42 amRNSDirector/PDMR Shareholding
6th Mar 20234:00 pmRNSDirector/PDMR Shareholding
6th Mar 202310:21 amRNSHolding(s) in Company
2nd Mar 20231:56 pmRNSIndivior Completes Opiant Transaction
2nd Mar 20238:43 amRNSCompletion of Share Repurchase Program
1st Mar 20234:35 pmRNSDirector/PDMR Shareholding
1st Mar 202310:09 amRNSTotal Voting Rights
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20234:18 pmRNSHolding(s) in Company
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares
22nd Feb 20234:52 pmRNSHolding(s) in Company
22nd Feb 20237:00 amRNSTransaction in Own Shares
21st Feb 202312:15 pmRNSIndivior to Participate in Conference
21st Feb 20239:09 amRNSHolding(s) in Company
21st Feb 20237:00 amRNSTransaction in Own Shares
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20233:00 pmRNSSID & Chair of Remuneration Committee
16th Feb 20237:00 amRNSFinal Results
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 20237:00 amRNSTransaction in Own Shares
13th Feb 20237:00 amRNSTransaction in Own Shares
10th Feb 20234:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.